A few words from someone who knows much more about medicine and biotech than the world of finance.

This situation is frustrating, infuriating, and depressing, but no matter how incompetent and self-serving the insiders, I can't believe that a molecule with apabetalone's credentials and FDA breakthrough status has not attracted a lot of interest from BP. It's not possible. My best guess scenario is that Don is negotiating with one or two companies, but they are taking advantage of the SP and not putting enough cash on the table.